Junshi Announces First Patient Dosed in China Trial of TROP2 ADC

Shanghai Junshi Bio reported the first patient has been dosed in a China Phase I trial of its anti-TROP2-Tub196 antibody drug conjugate. Junshi says TROP2 is a receptor expressed at high levels in several solid tumor cancers (including breast, gastric, NSCLC, SCLC, colon and pancreatic). Over-expression of TROP2 is correlated with poor prognosis clinically. In 2018, Junshi's Tuoyi (toripalimab) was the first China-developed anti-PD-1 mAb approved for China use. More details.... Stock Symbols: (HK: 1877; SHA: 688180) Share this with colleagues: // //